Ultragenyx Pharmaceutical Inc. Common Stock, also called Ultragenyx Pharmaceutical, is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Read More Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA. The listed name for RARE is Ultragenyx Pharmaceutical Inc. Common Stock.